PMID- 20937530
OWN - NLM
STAT- MEDLINE
DCOM- 20110516
LR  - 20220410
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 231
IP  - 1-2
DP  - 2011 Feb
TI  - Progressive multifocal leukoencephalopathy.
PG  - 73-7
LID - 10.1016/j.jneuroim.2010.09.021 [doi]
AB  - Progressive multifocal leukoencephalopathy (PML) is a disease of the central 
      nervous system (CNS) with destructive infection of oligodendrocytes by JC virus. 
      PML belongs to the opportunistic infections. It is observed in patients with HIV 
      infection, lymphoid malignancies, after organ- and stem cell transplantations and 
      more recently in the context of modern immune-therapies with monoclonal 
      antibodies (mAb) like natalizumab, rituximab, infliximab and efalizumab. The 
      natural course of PML is fatal within months. More recently, the Immune 
      Reconstitution Inflammatory Syndrome (IRIS) has been observed in patients with 
      HIV infection treated with combination antiretroviral therapy (cART) as well as 
      patients in whom the PML-inducing immune therapy has been terminated. In PML-IRIS 
      the immune system contributes to the elimination of JC virus from the CNS and if 
      PML-IRIS emerges, PML can be survived but can lead as well to catastrophic 
      outcomes with brain herniation and death. Therefore the management of IRIS 
      requires special knowledge in JC virus biology and patient care. JC virus 
      infection is possibly involved in a variety of additional neurological conditions 
      and cancer. Much will be learned within the next years that could change our view 
      on the understanding of JC virus and human disease.
CI  - Copyright (c) 2010 Elsevier B.V. All rights reserved.
FAU - Weissert, Robert
AU  - Weissert R
AD  - Department of Neurology, Geneva University Hospital, Micheli-du-Crest 24, 1211 
      Geneva 14, Switzerland. robert.weissert@hcuge.ch
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Natalizumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Humans
MH  - JC Virus/*immunology
MH  - Leukoencephalopathy, Progressive Multifocal/*immunology/*therapy/virology
MH  - Natalizumab
EDAT- 2010/10/13 06:00
MHDA- 2011/05/17 06:00
CRDT- 2010/10/13 06:00
PHST- 2010/10/13 06:00 [entrez]
PHST- 2010/10/13 06:00 [pubmed]
PHST- 2011/05/17 06:00 [medline]
AID - S0165-5728(10)00440-6 [pii]
AID - 10.1016/j.jneuroim.2010.09.021 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2011 Feb;231(1-2):73-7. doi: 10.1016/j.jneuroim.2010.09.021.